United States Pharmaceuticals

HOOKIPA Pharma Inc (HOOK)

Ticker: HOOK Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for HOOKIPA Pharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.3
Peters Malte Chief Executive Officer Executive Director
Transaction date
Sale
Price
337.50
Quantity 92,695 +35.7%
Value US$3,243,451
2.3
Peters Malte Officer Officer
Transaction date
Proposed sale
Price
202.55
Quantity 21,348
Value US$240,018
2.3
Peters Malte Officer Officer
Transaction date
Proposed sale
Price
90.81
Quantity 24,491
Value US$3,102,020
2.3
Peters Malte Chief Executive Officer Executive Director
Transaction date
Sale
Price
0.92
Quantity 29,176 -26.8%
Value US$26,842
3.8
Coelho Mary Theresa EVP and CFO Executive Director
Transaction date
Sale
Price
0.92
Quantity 13,609 -19.5%
Value US$12,520
1.0
Kandera Reinhard Chief Financial Officer Executive Director
Transaction date
Purchase
Price
0.73
Quantity 7,000 +19.4%
Value US$5,075
1.0
Kandera Reinhard Chief Financial Officer Executive Director
Transaction date
Purchase
Price
0.71
Quantity 8,000 +28.5%
Value US$5,712
0.9
Aldag Jorn Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.83
Quantity 5,000 +7.5%
Value US$4,142
0.9
Aldag Jorn Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.81
Quantity 5,000 +8.1%
Value US$4,050
0.9
Aldag Jorn Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.89
Quantity 5,000 +8.8%
Value US$4,450
0.9
Aldag Jorn Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.89
Quantity 5,000 +9.6%
Value US$4,456
1.0
Kandera Reinhard Chief Financial Officer Executive Director
Transaction date
Purchase
Price
0.88
Quantity 12,000 +74.6%
Value US$10,560
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
2.49
Quantity 2,205 -2.5%
Value US$5,490
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
2.49
Quantity 7,440 -8.1%
Value US$18,526
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
2.49
Quantity 5,304 -6.2%
Value US$13,207
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
13.12
Quantity 28,546 -0.8%
Value US$374,569
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
13.70
Quantity 52,690 -1.4%
Value US$721,616
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
13.91
Quantity 40,000 -1.1%
Value US$556,476
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
14.54
Quantity 40,534 -1.1%
Value US$589,263
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
14.60
Quantity 166,230 -4.3%
Value US$2,427,739
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
11.76
Quantity 16,478 -17.6%
Value US$193,781
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
11.70
Quantity 11,501 -15.2%
Value US$134,562
2.6
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
11.70
Quantity 380 -0.7%
Value US$4,446
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
12.45
Quantity 32,336 -0.8%
Value US$402,564
1.3
SOFINNOVA CAPITAL VI FCPR Large shareholder
Transaction date
Planned sale
Price
11.94
Quantity 12,483 -0.3%
Value US$149,102
2.6
Matushansky Igor Chief Medical Officer
Transaction date
Sale
Price
12.73
Quantity 5,500 -9.3%
Value US$69,992
3.1
Lilja Anders Sr. VP, Technical Development
Transaction date
Sale
Price
12.81
Quantity 7,568 -100.0%
Value US$96,932
3.1
Lilja Anders Sr. VP, Technical Development
Transaction date
Sale
Price
12.17
Quantity 4,075 -100.0%
Value US$49,601
2.9
Orlinger Klaus Sr. VP, Research
Transaction date
Sale
Price
12.02
Quantity 6,789 -100.0%
Value US$81,592
2.9
Orlinger Klaus Sr. VP, Research
Transaction date
Sale
Price
11.56
Quantity 1,711 -100.0%
Value US$19,781
2.9
Orlinger Klaus Sr. VP, Research
Transaction date
Sale
Price
11.30
Quantity 8,500 -100.0%
Value US$96,053
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
9.93
Quantity 10,404 -15.0%
Value US$103,312
Matushansky Igor Chief Medical Officer Officer
Transaction date
Sale
Price
7.87
Quantity 11,484 -20.9%
Value US$90,379
3.4
BAKER BROS. ADVISORS LP Former 10% owner
Transaction date
Purchase
Price
14.00
Quantity 820,729 New position
Value US$11,490,206
3.4
BAKER BROS. ADVISORS LP Former 10% owner
Transaction date
Purchase
Price
14.00
Quantity 72,128 New position
Value US$1,009,792
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-09 2025-08-19 S Sale
2.3
Peters Malte

Chief Executive Officer

Executive Director
92,695 +35.7%
337.50
US$3,243,451 		92,695 +35.7% 337.50 US$3,243,451
2025-08-27 2025-08-19 PrS Proposed sale
2.3
Peters Malte

Officer

Officer
21,348
202.55
US$240,018 		21,348 202.55 US$240,018
2025-08-27 2025-08-19 PrS Proposed sale
2.3
Peters Malte

Officer

Officer
24,491
90.81
US$3,102,020 		24,491 90.81 US$3,102,020
2025-07-23 2025-07-22 S Sale
2.3
Peters Malte

Chief Executive Officer

Executive Director
29,176 -26.8%
0.92
US$26,842 		29,176 -26.8% 0.92 US$26,842
2025-07-23 2025-07-22 S Sale
3.8
Coelho Mary Theresa

EVP and CFO

Executive Director
13,609 -19.5%
0.92
US$12,520 		13,609 -19.5% 0.92 US$12,520
2023-08-22 2023-08-21 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
7,000 +19.4%
0.73
US$5,075 		7,000 +19.4% 0.73 US$5,075
2023-08-17 2023-08-16 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
8,000 +28.5%
0.71
US$5,712 		8,000 +28.5% 0.71 US$5,712
2023-07-11 2023-07-11 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +7.5%
0.83
US$4,142 		5,000 +7.5% 0.83 US$4,142
2023-07-11 2023-07-07 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +8.1%
0.81
US$4,050 		5,000 +8.1% 0.81 US$4,050
2023-07-07 2023-07-05 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +8.8%
0.89
US$4,450 		5,000 +8.8% 0.89 US$4,450
2023-07-05 2023-07-03 B Purchase
0.9
Aldag Jorn

Chief Executive Officer

Executive Director
5,000 +9.6%
0.89
US$4,456 		5,000 +9.6% 0.89 US$4,456
2023-07-03 2023-06-30 B Purchase
1.0
Kandera Reinhard

Chief Financial Officer

Executive Director
12,000 +74.6%
0.88
US$10,560 		12,000 +74.6% 0.88 US$10,560
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
2,205 -2.5%
2.49
US$5,490 		2,205 -2.5% 2.49 US$5,490
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
7,440 -8.1%
2.49
US$18,526 		7,440 -8.1% 2.49 US$18,526
2022-01-12 2021-12-21 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
5,304 -6.2%
2.49
US$13,207 		5,304 -6.2% 2.49 US$13,207
2021-04-23 2021-04-21 S Sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
328,620 -9.4%
11.60
US$3,812,386 		328,620 -9.4% 11.60 US$3,812,386
2021-03-29 2021-03-25 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
28,546 -0.8%
13.12
US$374,569 		28,546 -0.8% 13.12 US$374,569
2021-03-26 2021-03-24 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
52,690 -1.4%
13.70
US$721,616 		52,690 -1.4% 13.70 US$721,616
2021-03-25 2021-03-23 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
40,000 -1.1%
13.91
US$556,476 		40,000 -1.1% 13.91 US$556,476
2021-03-24 2021-03-22 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
40,534 -1.1%
14.54
US$589,263 		40,534 -1.1% 14.54 US$589,263
2021-03-23 2021-03-19 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
166,230 -4.3%
14.60
US$2,427,739 		166,230 -4.3% 14.60 US$2,427,739
2020-12-18 2020-12-17 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
16,478 -17.6%
11.76
US$193,781 		16,478 -17.6% 11.76 US$193,781
2020-12-18 2020-12-17 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
11,501 -15.2%
11.70
US$134,562 		11,501 -15.2% 11.70 US$134,562
2020-12-18 2020-12-16 S Sale
2.6
Matushansky Igor

Chief Medical Officer

Officer
380 -0.7%
11.70
US$4,446 		380 -0.7% 11.70 US$4,446
2020-10-06 2020-10-02 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
300 -0.0%
10.00
US$3,000 		300 -0.0% 10.00 US$3,000
2020-09-17 2020-09-15 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
9,261 -0.2%
13.16
US$121,913 		9,261 -0.2% 13.16 US$121,913
2020-09-17 2020-09-15 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
32,336 -0.8%
12.45
US$402,564 		32,336 -0.8% 12.45 US$402,564
2020-07-22 2020-07-20 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
12,483 -0.3%
11.94
US$149,102 		12,483 -0.3% 11.94 US$149,102
2020-07-22 2020-06-29 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
3,280 -0.1%
11.78
US$38,628 		3,280 -0.1% 11.78 US$38,628
2020-07-01 2020-06-29 PlS Planned sale
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
3,280 -0.1%
11.78
US$38,628 		3,280 -0.1% 11.78 US$38,628
2020-01-31 2020-01-29 S Sale
2.6
Matushansky Igor

Chief Medical Officer
5,500 -9.3%
12.73
US$69,992 		5,500 -9.3% 12.73 US$69,992
2020-01-27 2020-01-23 S Sale
3.1
Lilja Anders

Sr. VP, Technical Development
7,568 -100.0%
12.81
US$96,932 		7,568 -100.0% 12.81 US$96,932
2020-01-27 2020-01-23 S Sale
3.1
Lilja Anders

Sr. VP, Technical Development
4,075 -100.0%
12.17
US$49,601 		4,075 -100.0% 12.17 US$49,601
2020-01-21 2020-01-21 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
6,789 -100.0%
12.02
US$81,592 		6,789 -100.0% 12.02 US$81,592
2020-01-21 2020-01-16 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
1,711 -100.0%
11.56
US$19,781 		1,711 -100.0% 11.56 US$19,781
2020-01-16 2020-01-14 S Sale
2.9
Orlinger Klaus

Sr. VP, Research
8,500 -100.0%
11.30
US$96,053 		8,500 -100.0% 11.30 US$96,053
2019-12-23 2019-12-19 S Sale Matushansky Igor

Chief Medical Officer

Officer
10,404 -15.0%
9.93
US$103,312 		10,404 -15.0% 9.93 US$103,312
2019-12-19 2019-12-17 S Sale Matushansky Igor

Chief Medical Officer

Officer
11,484 -20.9%
7.87
US$90,379 		11,484 -20.9% 7.87 US$90,379
2019-04-25 2019-04-23 B Purchase
0.5
Forbion Capital Fund II Cooperatief U.A.
Large shareholder
53,571 +2.2%
14.00
US$749,994 		53,571 +2.2% 14.00 US$749,994
2019-04-25 2019-04-23 B Purchase
1.3
SOFINNOVA CAPITAL VI FCPR
Large shareholder
357,142 +9.9%
14.00
US$4,999,988 		357,142 +9.9% 14.00 US$4,999,988
2019-04-23 2019-04-23 B Purchase
3.4
BAKER BROS. ADVISORS LP

Former 10% owner
820,729 New position
14.00
US$11,490,206 		820,729 New position 14.00 US$11,490,206
2019-04-23 2019-04-23 B Purchase
3.4
BAKER BROS. ADVISORS LP

Former 10% owner
72,128 New position
14.00
US$1,009,792 		72,128 New position 14.00 US$1,009,792
Explore more

More insider trading research around HOOKIPA Pharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America